keyword
MENU ▼
Read by QxMD icon Read
search

phase III carcinoma

keyword
https://www.readbyqxmd.com/read/28318951/a-comprehensive-analysis-of-programmed-cell-death-ligand-1-expression-with-the-clone-sp142-antibody-in-non-small-cell-lung-cancer%C3%A2-patients
#1
Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Mototsugu Shimokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment for non-small-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28315293/phase-ii-trial-of-intensity-modulated-radiotherapy-concurrent-with-chemotherapy-for-postoperative-node-positive-esophageal-squamous-cell-carcinoma
#2
Hua Tao, Yiqin Zhou, Chengyun Yao, Dayong Gu, Wei Chen, Jincheng Lu
The aim of this article is to evaluate the efficacy and toxicity of intensity-modulated radiotherapy concurrent with weekly docetaxel in patients with node-positive esophageal squamous cell carcinoma after radical surgery. Between January 2011 and December 2013, a total of 46 eligible patients were planned for enrollment. All the patients received intensity-modulated radiotherapy concurrent with weekly docetaxel (20 mg/m<sup>2</sup>). Patients were treated 5 days per week at 2.0 Gy/d. The total dose of external radiotherapy given was 50 Gy in 25 fractions...
March 8, 2017: Oncology Research
https://www.readbyqxmd.com/read/28293555/second-line-treatment-of-non-small-cell-lung-cancer-clinical-pathological-and-molecular-aspects-of-nintedanib
#3
REVIEW
Luis Corrales, Amanda Nogueira, Francesco Passiglia, Angela Listi, Christian Caglevic, Marco Giallombardo, Luis Raez, Edgardo Santos, Christian Rolfo
Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC)...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28288994/immunotherapy-beats-chemo-for-bladder-cancer
#4
(no author information available yet)
Patients with advanced urothelial carcinoma live 3 months longer, on average, when given pembrolizumab as a second-line treatment instead of chemotherapy. The finding is based on data from the first phase III trial to test an immunotherapeutic in these patients, which could lead to another label indication for the PD-1 inhibitor.
March 13, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28286925/cabozantinib-for-renal-cell-carcinoma-current-and-future-paradigms
#5
REVIEW
Ahmed Abdelaziz, Ulka Vaishampayan
Cabozantinib was approved by the FDA in April 2016 for the treatment of advanced renal cancer, pretreated with at least one prior antiangiogenic therapy. This is the first agent in the therapy of kidney cancer to show a statistically significant improvement in all three endpoints of clinical efficacy, response rate, progression free survival, and overall survival (OS), in a phase III randomized trial. The reporting of METEOR coincided with that of the Checkmate 025 study which randomized similarly eligible patients to receive nivolumab or everolimus 10 mg daily...
March 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28286921/treatment-strategies-for-metastatic-neuroendocrine-tumors-of-the-gastrointestinal-tract
#6
REVIEW
Mauro Cives, Jonathan Strosberg
The therapeutic landscape of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) has evolved significantly in recent years. Current and emerging treatment options include somatostatin analogs, radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the tyrosine kinase inhibitor sunitinib. Although high-quality data from phase III trials are lacking, cytotoxic agents are commonly used for the treatment of poorly differentiated neuroendocrine carcinomas and well-differentiated NETs originating in the pancreas...
March 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28280721/tissue-biomarkers-in-hepatocellular-tumors-which-when-and-how
#7
REVIEW
Luca Di Tommaso, Massimo Roncalli
Few tissue markers are currently available to pathologists in the study of hepatocellular tumors. These markers should be used carefully taking into consideration not only morphology but also, and sometimes even more important, the clinical setting where the lesion to be diagnosed had developed. Glypican-3, heat shock protein 70, and glutamine synthetase (GS) are markers currently used, as a single panel, to discriminate the nature of a <2 cm hepatocellular lesion lacking radiological features of hepatocellular carcinoma (HCC) detected in a cirrhotic patient under surveillance...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28276821/current-and-future-treatment-options-in-non-alcoholic-steatohepatitis-nash
#8
Nikos Lazaridis, Emmanuel Tsochatzis
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that can progress to cirrhosis and hepatocellular carcinoma. Diagnosis of NASH requires a liver biopsy and is defined as presence of hepatic steatosis, ballooning and lobular inflammation with or without fibrosis. Although NASH is the most common cause of liver disease in the west world and among the top three indications for liver transplantation, there are no universally accepted pharmacological therapies and therapeutic advances have been slow...
April 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28272463/pd-1-inhibitors-increase-the-incidence-and-risk-of-pneumonitis-in-cancer-patients-in-a-dose-independent-manner-a-meta-analysis
#9
Jiaying Wu, Dongsheng Hong, Xiangnan Zhang, Xiaoyang Lu, Jing Miao
Therapies that targeted PD-1 have shown remarkable rates of durable clinical responses in patients with various tumor types. However, the extent and knowledge of pulmonary toxicities associated with PD-1 blockade, mainly manifested as pneumonitis, remains obscure. In this study, a total of 6360 subjects from 16 phase II/III clinical trials were pooled for meta-analysis to evaluate the overall incidence and risk of PD-1 inhibitors-related pneumonitis in cancer patients. The incidence of pneumonitis during anti-PD-1 immunotherapy was 2...
March 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28270162/a-phase-ii-study-of-concurrent-chemoradiotherapy-combined-with-a-weekly-paclitaxel-and-5-fluorouracil-regimen-to-treat-patients-with-advanced-oesophageal-carcinoma
#10
Yi Xia, Yun-Hai Li, Yun Chen, Jun-Hua Zhang, Qi Liu, Jia-Ying Deng, Ta-Shan Ai, Han-Ting Zhu, Jian-Hong Fan, Harun Badakhshi, Kuai-le Zhao
BACKGROUND: A phase II study was performed to investigate the safety and efficacy of weekly doses of combined paclitaxel and 5-fluorouracil (5-FU) with concurrent radiation therapy, followed by 2 cycles of consolidation chemotherapy to treat patients with advanced oesophageal carcinoma. METHODS: The eligibility criteria included local, advanced, newly diagnosed and postoperative local regional lymph node metastasis; an Eastern Cooperative Oncology Group (ECOG) score of ≤ 2; and adequate organ function...
March 7, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28251375/adjuvant-therapy-for-locally-advanced-gastric-cancer
#11
REVIEW
Toru Aoyama, Takaki Yoshikawa
D2 gastrectomy is now the globally accepted surgical standard for locally advanced gastric cancer. However, since 2000, different evidence has emerged regarding the efficacy of adjuvant chemoradiation, perioperative adjuvant chemotherapy, and postoperative chemotherapy for locally advanced gastric cancer. This review summarizes the background, current status, and future perspectives of adjuvant therapy for locally advanced gastric cancer. The Intergroup 0116 study was the first to show the significant overall survival benefits of adjuvant (chemoradiation) therapy for gastric cancer...
March 1, 2017: Surgery Today
https://www.readbyqxmd.com/read/28249612/do-selective-radiation-dose-escalation-and-tumour-hypoxia-status-impact-the-loco-regional-tumour-control-after-radio-chemotherapy-of-head-neck-tumours-the-escalox-protocol
#12
Steffi U Pigorsch, Jan J Wilkens, Severin Kampfer, Victoria Kehl, Alexander Hapfelmeier, Christian Schläger, Henning Bier, Markus Schwaiger, Stephanie E Combs
BACKGROUND: Standard of care primary treatment of carcinoma of locally advanced squamous cell head and neck cancer (LAHNSCC) consists of platinum-based concomitant chemo-irradiation. Despite progress in the treatment of LAHNSCC using modern radiotherapy techniques the outcome remains still poor. Using IMRT with SIB the escalation of total dose to the GTV is possible with the aim to improve clinical outcome. This study tests the hypothesis if radiation dose escalation to the GTV improves 2-year-LRC and -OS after concomitant chemo-irradiation...
March 1, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28246756/-first-line-therapy-in-advanced-renal-cell-carcinoma-a-randomized-open-label-phase%C3%A2-iii-study-evaluating-the-efficacy-and-safety-of-pembrolizumab-mk-3475-in-combination-with-axitinib-compared-to-sunitinib-monotherapy-as-first-line-treatment-for-locally-advanced
#13
https://www.readbyqxmd.com/read/28235726/adjuvant-chemotherapy-in-patients-with-locoregionally-advanced-nasopharyngeal-carcinoma-long-term-results-of-a-phase-3-multicentre-randomised-controlled-trial
#14
Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma
AIM OF THE STUDY: Previous results from our trial showed that adjuvant cisplatin and fluorouracil chemotherapy did not significantly improve survival after concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) at 2 years. Here, we present the data of long-term survival and late toxicities to further assess the ultimate therapeutic index of adjuvant chemotherapy (AC). METHODS: Patients with stage III-IVB (except T3-4N0) NPC were randomly assigned to receive CCRT plus AC or CCRT only at seven institutions in China...
February 21, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28230776/effects-and-side-effects-of-using-sorafenib-and-sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#15
REVIEW
Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E Magnusson
In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles...
February 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28214653/neoadjuvant-chemotherapy-followed-by-concurrent-chemoradiotherapy-versus-concurrent-chemoradiotherapy-alone-in-locoregionally-advanced-nasopharyngeal-carcinoma-a-phase-iii-multicentre-randomised-controlled-trial
#16
Su-Mei Cao, Qi Yang, Ling Guo, Hai-Qiang Mai, Hao-Yuan Mo, Ka-Jia Cao, Chao-Nan Qian, Chong Zhao, Yan-Qun Xiang, Xiu-Ping Zhang, Zhi-Xiong Lin, Wei-Xiong Li, Qing Liu, Fang Qiu, Rui Sun, Qiu-Yan Chen, Pei-Yu Huang, Dong-Hua Luo, Yi-Jun Hua, Yi-Shan Wu, Xing Lv, Lin Wang, Wei-Xiong Xia, Lin-Quan Tang, Yan-Fang Ye, Ming-Yuan Chen, Xiang Guo, Ming-Huang Hong
BACKGROUND: The role of neoadjuvant chemotherapy (NACT) for locoregionally advanced nasopharyngeal carcinoma (NPC) is unclear. We aimed to evaluate the feasibility and efficacy of NACT followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced NPC. METHODS: Patients with stage III-IVB (excluding T3N0-1) NPC were randomly assigned to receive NACT followed by CCRT (investigational arm) or CCRT alone (control arm). Both arms were treated with 80 mg/m(2) cisplatin every 3 weeks concurrently with radiotherapy...
February 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28211921/metronomic-capecitabine-versus-best-supportive-care-as-second-line-treatment-in-hepatocellular-carcinoma-a-retrospective-study
#17
Andrea Casadei Gardini, Flavia Foca, Mario Scartozzi, Nicola Silvestris, Emiliano Tamburini, Luca Faloppi, Oronzo Brunetti, Britt Rudnas, Salvatore Pisconti, Martina Valgiusti, Giorgia Marisi, Francesco Giuseppe Foschi, Giorgio Ercolani, Davide Tassinari, Stefano Cascinu, Giovanni Luca Frassineti
Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7-3.5). Median overall survival was 12...
February 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28210091/long-term-results-of-paclitaxel-plus-cisplatin-with-concurrent-radiotherapy-for-loco-regional-esophageal-squamous-cell-carcinoma
#18
Han-Ting Zhu, Da-Shan Ai, Hua-Rong Tang, Harun Badakhshi, Jian-Hong Fan, Jia-Ying Deng, Jun-Hua Zhang, Yun Chen, Zhen Zhang, Yi Xia, Xiao-Mao Guo, Guo-Liang Jiang, Kuai-Le Zhao
AIM: To evaluate the long-term effectiveness and late toxicities of paclitaxel (PTX) plus cisplatin (DDP) with concurrent radiotherapy for locally advanced esophageal squamous cancer. METHODS: Between 2008 and 2011, 76 patients were enrolled in a phase II study on the treatment of loco-regionally advanced esophageal cancer with radiotherapy (68.4 Gy/44 fractions or 61.2 Gy/34 fractions) combined with 4-cycle chemotherapy consisting of DDP (25 mg/m(2) per day for 3 d) and PTX (175 mg/m(2) for 3 h)...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28203424/a-phase-iii-multicenter-randomized-controlled-trial-of-neo-adjuvant-chemotherapy-paclitaxel-plus-cisplatin-versus-surgery-alone-for-stage-iia-iiib-esophageal-squamous-cell-carcinoma
#19
Yan Zheng, Yin Li, Xianben Liu, Ruixiang Zhang, Zongfei Wang, Haibo Sun, Shilei Liu
BACKGROUND: The survival benefits of neoadjuvant chemotherapy (NAC) for esophagus squamous cell carcinoma (ESCC) remains controversial. The surgical procedure was not well defined in NAC strategy, in past trials. The different surgical procedure and different levels of lymphadenectomy may decrease the survival benefits from NAC. The new chemotherapy regimen with paclitaxel is promising. The purpose of this study is to confirm the superiority of paclitaxel, cisplatin and McKeown esophagectomy with total two-field lymphadenectomy compared with surgery alone for ESCC...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28202000/safety-and-efficacy-of-lobaplatin-combined-with-5-fluorouracil-as-first-line-induction-chemotherapy-followed-by-lobaplatin-radiotherapy-in-locally-advanced-nasopharyngeal-carcinoma-preliminary-results-of-a-prospective-phase-ii-trial
#20
Liang-Ru Ke, Wei-Xiong Xia, Wen-Ze Qiu, Xin-Jun Huang, Jing Yang, Ya-Hui Yu, Hu Liang, Guo-Ying Liu, Yan-Fang Ye, Yan-Qun Xiang, Xiang Guo, Xing Lv
BACKGROUND: Due to improvements in imaging and radiological techniques as well as the use of chemotherapy, distant metastasis has become the predominant mode of treatment failure in patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Platinum-based systemic chemotherapy has shown survival benefits and is now the standard strategy for systemic therapy in patients with LA-NPC. Notably, the third-generation platinum reagent lobaplatin has shown anti-tumor effects in several solid tumors with lower incidences of gastrointestinal, hepatic and renal toxicity relative to other platinum drugs...
February 15, 2017: BMC Cancer
keyword
keyword
86070
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"